<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20200921048789N2</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2021-04-12</date_registration>
      <primary_sponsor>Artesh University of Medical Sciences</primary_sponsor>
      <public_title>Evaluation of anesthesia quality with three methods: "propofol + fentanyl " Vs "propofol + fentanyl + lidocaine" Vs "propofol + fentanyl + lidocaine + ketamine" in patients referred to the scoping ward</public_title>
      <acronym></acronym>
      <scientific_title>Evaluation of cough frequency and duration of recovery with three anesthesia methods: "Propofol + Fentanyl", "Propofol + Fentanyl + Lidocaine" and "Propofol + Fentanyl + Lidocaine + Ketamine" in patients referred to the scoping ward</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2021-04-21</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>100</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/54948</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: The sample size in this study is at least 100 patients who will be admitted to the study by block randomization method. For this purpose, the letter A is used to place patients in the group "propofol + fentanyl", the letter B is used in the group "propofol + fentanyl + lidocaine" and the letter C is used in the group "propofol + fentanyl + lidocaine + ketamine". The size of all blocks is equal and in this three-group experiment, we use 6 blocks (including two people in group A, two people in group B and two people in group C) that were obtained using random sequence generation software. Also, in order to hide the random sequence on the participants, opaque sealed envelopes sealed with random sequences (SNOSE) are used and each sequence is recorded on a card and the cards are placed in the envelopes respectively. Based on the order of entry of eligible participants in the research, the envelopes are opened in order and the assigned group of the participant is determined, Blinding description: In this study, patients are unaware of the type of sedation drug for scoping, but the specialist physician, treatment staff, and research team are aware of the type of drug combination that was randomly selected for the patient.</study_design>
      <phase>3</phase>
      <hc_freetext>.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: Group A includes patients in whom propofol + fentanyl has been used for sedation for scoping. Propofol-lipuro: initial dose 1mg/kg and repeat dose 0.5 mg/kg every 3-5 min and Fentanyl (Rotexmedica): 0.5 mic g/kg single dose. Intervention 2: Intervention group: Group B includes patients in whom propofol + fentanyl + lidocaine have been used for sedation for scoping. Propofol-lipuro: initial dose 1mg/kg and repeat dose 0.5 mg/kg every 3-5 min and Fentanyl(rotexmedica): 0.5 mic g/kg single dose and Lidocaine (pasteur): 1.5 mg/kg single dose. Intervention 3: Intervention group: Group C includes patients in whom propofol + fentanyl + lidocaine + ketamine have been used for sedation for scoping.  Propofol(lipuro): initial dose 0.5mg/kg and repeat dose 0.25 mg/kg every 3-5 min and Fentanyl (Rotexmedica): 0.25 mic g/kg single dose and Lidocaine (pasteur): 0.75 mg/kg single dose and ketamine (Rotexmedica) 0.5 mg/kg single dose.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
Research data can be published at the end of the study after identifying individuals

When:
After the end of the research and publication of the article

To whom:
All researchers and physicians engaged in the field of anesthesia and intensive care

Conditions:
Only for research and treatment purposes and by mentioning the names of those involved in this study

Where to obtain:
By email to Dr. Mohammad Reza Rafiei at Rafiei_mohamadreza@yahoo.com

How to obtain:
After receiving the email, the applicant's request will be reviewed and if approved, the information will be sent to them

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Mohammadreza rafiei</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Aja univercity of medical science, Etemadzadeh St., West Fatemi Ave.</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1411718541</zip>
        <telephone>+98 21 8609 6350</telephone>
        <email>Rafiei_mohamadreza@yahoo.com</email>
        <affiliation>Artesh University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Mohammadreza Rafiiei</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Aja univercity of medical science, Etemadzadeh St., West Fatemi Ave.</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1411718541</zip>
        <telephone>+98 21 8660 9635</telephone>
        <email>Rafiei_mohamadreza@yahoo.com</email>
        <affiliation>Artesh University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>All patients who are candidates for scoping in 501 Army Hospital in 2021</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>70 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Age under 18 and over 70 years
ASA classification 4 or 5
History of uncontrolled blood pressure
History of Chronic Obstructive Pulmonary Disease (COPD)
History of psychotic or neurological disorders
History of seizures
History of use of drugs affecting the central nervous system
Pregnancy</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code></hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword></hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: Group A includes patients in whom propofol + fentanyl has been used for sedation for scoping. Propofol-lipuro: initial dose 1mg/kg and repeat dose 0.5 mg/kg every 3-5 min and Fentanyl (Rotexmedica): 0.5 mic g/kg single dose.</i_keyword>
      <i_keyword>Intervention group: Group B includes patients in whom propofol + fentanyl + lidocaine have been used for sedation for scoping. Propofol-lipuro: initial dose 1mg/kg and repeat dose 0.5 mg/kg every 3-5 min and Fentanyl(rotexmedica): 0.5 mic g/kg single dose and Lidocaine (pasteur): 1.5 mg/kg single dose.</i_keyword>
      <i_keyword>Intervention group: Group C includes patients in whom propofol + fentanyl + lidocaine + ketamine have been used for sedation for scoping.  Propofol(lipuro): initial dose 0.5mg/kg and repeat dose 0.25 mg/kg every 3-5 min and Fentanyl (Rotexmedica): 0.25 mic g/kg single dose and Lidocaine (pasteur): 0.75 mg/kg single dose and ketamine (Rotexmedica) 0.5 mg/kg single dose.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Frequency of cough. Timepoint: During and after the intervention. Method of measurement: View on the patient bed.</prim_outcome>
      <prim_outcome>Duration of recovery. Timepoint: After intervention. Method of measurement: View on the patient bed.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>O2 saturation. Timepoint: During and after the intervention. Method of measurement: view on the patient's bed.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Artesh University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2021-02-16</approval_date>
        <contact_name>کمیته اخلاق دانشگاه علوم پزشکی ارتش جمهوری اسلامی ایران</contact_name>
        <contact_address>Aja univercity of medical science, Etemadzadeh St., West Fatemi Ave., Tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
